{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:41:51Z","timestamp":1790790111231,"version":"4.1.0"},"reference-count":70,"publisher":"American Association for Cancer Research (AACR)","issue":"11","funder":[{"DOI":"10.13039\/100004917","name":"CPRIT","doi-asserted-by":"publisher","award":["RP190208"],"award-info":[{"award-number":["RP190208"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Pollack Foundation"},{"DOI":"10.13039\/100000054","name":"NCI","doi-asserted-by":"publisher","award":["R01 CA251928"],"award-info":[{"award-number":["R01 CA251928"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Stand Up To Cancer Innovative Research grant","award":["SU2C-AACR-IRG 10-16"],"award-info":[{"award-number":["SU2C-AACR-IRG 10-16"]}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Cirrhosis is a high-risk state for hepatocellular carcinoma (HCC) development and represents an opportunity to prevent cancer. In the precancerous state of cirrhosis, there is an accumulation of neoantigens that may be specifically targetable through immunotherapy. We asked whether immune checkpoint inhibition could prevent tumorigenesis in a mouse model of diethylnitrosamine and carbon tetrachloride\u2013induced HCC. We found that initiation of anti-PD-1 therapy prior to tumorigenesis could prevent up to 46% of liver tumors. This significant reduction in tumor burden was accompanied by infiltration of CD4+ Th cells and CD8+ cytotoxic T cells into the liver parenchyma. Importantly, anti-PD-1 therapy did not exacerbate liver dysfunction or worsen overall health in this liver disease model. Given the safety and preservation of quality of life observed with long-term immunotherapy use, an immunotherapy chemoprevention strategy is likely associated with a low risk-to-benefit ratio and high value care in select patients. These results encourage a prevention trial in cirrhotic patients with the highest risk of developing HCC.<\/jats:p>\n                  <jats:p>See related Spotlight by Mohammed et al., p. 897<\/jats:p>","DOI":"10.1158\/1940-6207.capr-20-0200","type":"journal-article","created":{"date-parts":[[2020,8,24]],"date-time":"2020-08-24T13:30:16Z","timestamp":1598275816000},"page":"911-922","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Immune Checkpoint Inhibition is Safe and Effective for Liver Cancer Prevention in a Mouse Model of Hepatocellular Carcinoma"],"prefix":"10.1158","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5273-1428","authenticated-orcid":false,"given":"Andrew S.","family":"Chung","sequence":"first","affiliation":[{"name":"1Children's Research Institute, Departments of Pediatrics and Internal Medicine, Center for Regenerative Science and Medicine, University of Texas Southwestern Medical Center, Dallas, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"Mettlen","sequence":"additional","affiliation":[{"name":"2Department of Cell Biology, University of Texas Southwestern Medical Center, Dallas, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7184-0053","authenticated-orcid":false,"given":"Debolina","family":"Ganguly","sequence":"additional","affiliation":[{"name":"3Department of Surgery, University of Texas Southwestern Medical Center, Dallas, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianshi","family":"Lu","sequence":"additional","affiliation":[{"name":"4Quantitative Biomedical Research Center, Department of Population and Data Sciences, University of Texas Southwestern Medical Center, Dallas, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Wang","sequence":"additional","affiliation":[{"name":"4Quantitative Biomedical Research Center, Department of Population and Data Sciences, University of Texas Southwestern Medical Center, Dallas, Texas."},{"name":"5Center for the Genetics of Host Defense, University of Texas Southwestern Medical Center, Dallas, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2704-2377","authenticated-orcid":false,"given":"Rolf A.","family":"Brekken","sequence":"additional","affiliation":[{"name":"3Department of Surgery, University of Texas Southwestern Medical Center, Dallas, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Hsiehchen","sequence":"additional","affiliation":[{"name":"6Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Zhu","sequence":"additional","affiliation":[{"name":"1Children's Research Institute, Departments of Pediatrics and Internal Medicine, Center for Regenerative Science and Medicine, University of Texas Southwestern Medical Center, Dallas, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2020,11,3]]},"reference":[{"key":"2022060815414206100_bib1","doi-asserted-by":"crossref","first-page":"16018","DOI":"10.1038\/nrdp.2016.18","article-title":"Hepatocellular carcinoma","volume":"2","author":"Llovet","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"2022060815414206100_bib2","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1056\/NEJMra1713263","article-title":"Hepatocellular carcinoma","volume":"380","author":"Villanueva","year":"2019","journal-title":"N Engl J Med"},{"key":"2022060815414206100_bib3","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1053\/j.gastro.2013.01.021","article-title":"Prognostic gene expression signature for patients with hepatitis C-related early-stage cirrhosis","volume":"144","author":"Hoshida","year":"2013","journal-title":"Gastroenterology"},{"key":"2022060815414206100_bib4","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.ccell.2016.11.004","article-title":"Molecular liver cancer prevention in cirrhosis by organ transcriptome analysis and lysophosphatidic acid pathway inhibition","volume":"30","author":"Nakagawa","year":"2016","journal-title":"Cancer Cell"},{"key":"2022060815414206100_bib5","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.jhep.2018.07.024","article-title":"Development of models estimating the risk of hepatocellular carcinoma after antiviral treatment for hepatitis C","volume":"69","author":"Ioannou","year":"2018","journal-title":"J Hepatol"},{"key":"2022060815414206100_bib6","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.jhep.2019.05.008","article-title":"Models estimating risk of hepatocellular carcinoma in patients with alcohol or NAFLD-related cirrhosis for risk stratification","volume":"71","author":"Ioannou","year":"2019","journal-title":"J Hepatol"},{"key":"2022060815414206100_bib7","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/nrgastro.2013.143","article-title":"Chemopreventive strategies in hepatocellular carcinoma","volume":"11","author":"Singh","year":"2014","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2022060815414206100_bib8","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial","volume":"389","author":"El-Khoueiry","year":"2017","journal-title":"Lancet"},{"key":"2022060815414206100_bib9","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"key":"2022060815414206100_bib10","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med"},{"key":"2022060815414206100_bib11","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med"},{"key":"2022060815414206100_bib12","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"2022060815414206100_bib13","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S1470-2045(18)30351-6","article-title":"Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial","volume":"19","author":"Zhu","year":"2018","journal-title":"Lancet Oncol"},{"key":"2022060815414206100_bib14","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1001\/jamaoncol.2019.2187","article-title":"Five-year survival and correlates among patients with advanced melanoma, renal cell carcinoma, or non-small cell lung cancer treated with nivolumab","volume":"5","author":"Topalian","year":"2019","journal-title":"JAMA Oncol"},{"key":"2022060815414206100_bib15","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1126\/science.aaa4971","article-title":"Neoantigens in cancer immunotherapy","volume":"348","author":"Schumacher","year":"2015","journal-title":"Science"},{"key":"2022060815414206100_bib16","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/nrc.2017.74","article-title":"Targeting neoantigens to augment antitumour immunity","volume":"17","author":"Yarchoan","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"2022060815414206100_bib17","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.cell.2014.12.033","article-title":"Molecular and genetic properties of tumors associated with local immune cytolytic activity","volume":"160","author":"Rooney","year":"2015","journal-title":"Cell"},{"key":"2022060815414206100_bib18","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1038\/s41588-019-0532-6","article-title":"Lack of detectable neoantigen depletion signals in the untreated cancer genome","volume":"51","author":"Van den Eynden","year":"2019","journal-title":"Nat Genet"},{"key":"2022060815414206100_bib19","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s13045-019-0787-5","article-title":"Tumor neoantigens: from basic research to clinical applications","volume":"12","author":"Jiang","year":"2019","journal-title":"J Hematol Oncol"},{"key":"2022060815414206100_bib20","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.cell.2017.09.028","article-title":"Tumor and microenvironment evolution during immunotherapy with nivolumab","volume":"171","author":"Riaz","year":"2017","journal-title":"Cell"},{"key":"2022060815414206100_bib21","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"key":"2022060815414206100_bib22","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1604958","article-title":"Mutations associated with acquired resistance to PD-1 blockade in melanoma","volume":"375","author":"Zaretsky","year":"2016","journal-title":"N Engl J Med"},{"key":"2022060815414206100_bib23","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1126\/science.aaf1490","article-title":"Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade","volume":"351","author":"McGranahan","year":"2016","journal-title":"Science"},{"key":"2022060815414206100_bib24","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.cell.2019.03.026","article-title":"Somatic mutations increase hepatic clonal fitness and regeneration in chronic liver disease","volume":"177","author":"Zhu","year":"2019","journal-title":"Cell"},{"key":"2022060815414206100_bib25","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/s41586-019-1670-9","article-title":"Somatic mutations and clonal dynamics in healthy and cirrhotic human liver","volume":"574","author":"Brunner","year":"2019","journal-title":"Nature"},{"key":"2022060815414206100_bib26","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/j.cell.2017.05.046","article-title":"Comprehensive and integrative genomic characterization of hepatocellular carcinoma","volume":"169","author":"Cancer Genome Atlas Research Network","year":"2017","journal-title":"Cell"},{"key":"2022060815414206100_bib27","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1093\/bioinformatics\/btp324","article-title":"Fast and accurate short read alignment with Burrows-Wheeler transform","volume":"25","author":"Li","year":"2009","journal-title":"Bioinformatics"},{"key":"2022060815414206100_bib28","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/nbt.2514","article-title":"Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples","volume":"31","author":"Cibulskis","year":"2013","journal-title":"Nat Biotechnol"},{"key":"2022060815414206100_bib29","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1101\/gr.129684.111","article-title":"VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing","volume":"22","author":"Koboldt","year":"2012","journal-title":"Genome Res"},{"key":"2022060815414206100_bib30","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1093\/bioinformatics\/btt183","article-title":"Shimmer: detection of genetic alterations in tumors using next-generation sequence data","volume":"29","author":"Hansen","year":"2013","journal-title":"Bioinformatics"},{"key":"2022060815414206100_bib31","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/nmeth.3505","article-title":"SpeedSeq: ultra-fast personal genome analysis and interpretation","volume":"12","author":"Chiang","year":"2015","journal-title":"Nat Methods"},{"key":"2022060815414206100_bib32","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1093\/bioinformatics\/btv710","article-title":"Manta: rapid detection of structural variants and indels for germline and cancer sequencing applications","volume":"32","author":"Chen","year":"2016","journal-title":"Bioinformatics"},{"key":"2022060815414206100_bib33","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1093\/bioinformatics\/bts271","article-title":"Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs","volume":"28","author":"Saunders","year":"2012","journal-title":"Bioinformatics"},{"key":"2022060815414206100_bib34","doi-asserted-by":"crossref","first-page":"e164","DOI":"10.1093\/nar\/gkq603","article-title":"ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data","volume":"38","author":"Wang","year":"2010","journal-title":"Nucleic Acids Res"},{"key":"2022060815414206100_bib35","doi-asserted-by":"crossref","first-page":"eaaz3199","DOI":"10.1126\/sciimmunol.aaz3199","article-title":"Tumor neoantigenicity assessment with CSiN score incorporates clonality and immunogenicity to predict immunotherapy outcomes","volume":"5","author":"Lu","year":"2020","journal-title":"Sci Immunol"},{"key":"2022060815414206100_bib36","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: ultrafast universal RNA-seq aligner","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics"},{"key":"2022060815414206100_bib37","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/bioinformatics\/btt656","article-title":"featureCounts: an efficient general purpose program for assigning sequence reads to genomic features","volume":"30","author":"Liao","year":"2014","journal-title":"Bioinformatics"},{"key":"2022060815414206100_bib38","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/carcin\/7.2.215","article-title":"Interstrain differences in susceptibility to liver carcinogenesis initiated by N-nitrosodiethylamine and its promotion by phenobarbital in C57BL\/6NCr, C3H\/HeNCrMTV- and DBA\/2NCr mice","volume":"7","author":"Diwan","year":"1986","journal-title":"Carcinogenesis"},{"key":"2022060815414206100_bib39","doi-asserted-by":"crossref","first-page":"292","DOI":"10.4049\/jimmunol.1800878","article-title":"Improved multiplex immunohistochemistry for immune microenvironment evaluation of mouse formalin-fixed, paraffin-embedded tissues","volume":"202","author":"Sorrelle","year":"2019","journal-title":"J Immunol"},{"key":"2022060815414206100_bib40","first-page":"1208","article-title":"Dynamic evaluation of liver fibrosis to assess the risk of hepatocellular carcinoma in patients with chronic hepatitis C who achieved sustained virologic response","volume":"70","author":"Toyoda","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2022060815414206100_bib41","doi-asserted-by":"crossref","first-page":"234","DOI":"10.3350\/cmh.2018.0108","article-title":"Development and surveillance of hepatocellular carcinoma in patients with sustained virologic response after antiviral therapy for chronic hepatitis C","volume":"25","author":"Na","year":"2019","journal-title":"Clin Mol Hepatol"},{"key":"2022060815414206100_bib42","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/j.1365-2613.2009.00656.x","article-title":"Experimental mouse models for hepatocellular carcinoma research","volume":"90","author":"Heindryckx","year":"2009","journal-title":"Int J Exp Pathol"},{"key":"2022060815414206100_bib43","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/0163-7258(96)00062-9","article-title":"N-nitrosodiethylamine mechanistic data and risk assessment: bioactivation, DNA-adduct formation, mutagenicity, and tumor initiation","volume":"71","author":"Verna","year":"1996","journal-title":"Pharmacol Ther"},{"key":"2022060815414206100_bib44","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13073-017-0424-2","article-title":"Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden","volume":"9","author":"Chalmers","year":"2017","journal-title":"Genome Med"},{"key":"2022060815414206100_bib45","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.jhep.2018.06.009","article-title":"Mutational landscape of a chemically-induced mouse model of liver cancer","volume":"69","author":"Connor","year":"2018","journal-title":"J Hepatol"},{"key":"2022060815414206100_bib46","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.devcel.2018.01.010","article-title":"The polyploid state plays a tumor-suppressive role in the liver","volume":"44","author":"Zhang","year":"2018","journal-title":"Dev Cell"},{"key":"2022060815414206100_bib47","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1007\/s00204-015-1543-4","article-title":"Experimental models of liver fibrosis","volume":"90","author":"Yanguas","year":"2016","journal-title":"Arch Toxicol"},{"key":"2022060815414206100_bib48","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0300-483X(03)00157-4","article-title":"Carbon tetrachloride-induced lipid peroxidation: eicosanoid formation and their regulation by antioxidant nutrients","volume":"189","author":"Basu","year":"2003","journal-title":"Toxicology"},{"key":"2022060815414206100_bib49","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1080\/713611034","article-title":"Hepatotoxicity and mechanism of action of haloalkanes: carbon tetrachloride as a toxicological model","volume":"33","author":"Weber","year":"2003","journal-title":"Crit Rev Toxicol"},{"key":"2022060815414206100_bib50","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1600-065X.2010.00923.x","article-title":"The PD-1 pathway in tolerance and autoimmunity","volume":"236","author":"Francisco","year":"2010","journal-title":"Immunol Rev"},{"key":"2022060815414206100_bib51","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"2022060815414206100_bib52","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1038\/nm.3909","article-title":"The prognostic landscape of genes and infiltrating immune cells across human cancers","volume":"21","author":"Gentles","year":"2015","journal-title":"Nat Med"},{"key":"2022060815414206100_bib53","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/nature10599","article-title":"Senescence surveillance of pre-malignant hepatocytes limits liver cancer development","volume":"479","author":"Kang","year":"2011","journal-title":"Nature"},{"key":"2022060815414206100_bib54","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1158\/2159-8290.CD-19-0074","article-title":"\u03b2-catenin activation promotes immune escape and resistance to anti-PD-1 therapy in hepatocellular carcinoma","volume":"9","author":"Ruiz de Galarreta","year":"2019","journal-title":"Cancer Discov"},{"key":"2022060815414206100_bib55","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"2022060815414206100_bib56","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"Bruix","year":"2017","journal-title":"Lancet"},{"key":"2022060815414206100_bib57","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1056\/NEJMoa1717002","article-title":"Cabozantinib in patients with advanced and progressing hepatocellular carcinoma","volume":"379","author":"Abou-Alfa","year":"2018","journal-title":"N Engl J Med"},{"key":"2022060815414206100_bib58","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S1470-2045(15)00050-9","article-title":"Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial","volume":"16","author":"Zhu","year":"2015","journal-title":"Lancet Oncol"},{"key":"2022060815414206100_bib59","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s40262-019-00748-2","article-title":"Clinical pharmacokinetics and pharmacodynamics of immune checkpoint inhibitors","volume":"58","author":"Centanni","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"2022060815414206100_bib60","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/s41591-019-0357-y","article-title":"A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma","volume":"25","author":"Huang","year":"2019","journal-title":"Nat Med"},{"key":"2022060815414206100_bib61","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1200\/EDBK_201435","article-title":"Immunotherapy in older adults with advanced cancers: implications for clinical decision-making and future research","volume":"38","author":"Kanesvaran","year":"2018","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2022060815414206100_bib62","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1148\/radiol.2018181494","article-title":"Liver imaging reporting and data system (LI-RADS) version 2018: imaging of hepatocellular carcinoma in at-risk patients","volume":"289","author":"Chernyak","year":"2018","journal-title":"Radiology"},{"key":"2022060815414206100_bib63","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1053\/j.gastro.2019.02.049","article-title":"Surveillance for hepatocellular carcinoma: current best practice and future direction","volume":"157","author":"Kanwal","year":"2019","journal-title":"Gastroenterology"},{"key":"2022060815414206100_bib64","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/0471141755.ph1430s66","article-title":"The DEN and CCl4 -induced mouse model of fibrosis and inflammation-associated hepatocellular carcinoma","volume":"66","author":"Uehara","year":"2014","journal-title":"Curr Protoc Pharmacol"},{"key":"2022060815414206100_bib65","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1177\/0023677215570086","article-title":"Diethylnitrosamine (DEN)-induced carcinogenic liver injury in mice","volume":"49","author":"Tolba","year":"2015","journal-title":"Lab Anim"},{"key":"2022060815414206100_bib66","doi-asserted-by":"crossref","first-page":"e0203879","DOI":"10.1371\/journal.pone.0203879","article-title":"Fibrosis-associated hepatocarcinogenesis revisited: Establishing standard medium-term chemically-induced male and female models","volume":"13","author":"Romualdo","year":"2018","journal-title":"PLoS One"},{"key":"2022060815414206100_bib67","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1056\/NEJMra1001683","article-title":"Hepatocellular carcinoma","volume":"365","author":"El-Serag","year":"2011","journal-title":"N Engl J Med"},{"key":"2022060815414206100_bib68","doi-asserted-by":"crossref","first-page":"14771","DOI":"10.1073\/pnas.0706578104","article-title":"Distinct pathways of genomic progression to benign and malignant tumors of the liver","volume":"104","author":"Tward","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022060815414206100_bib69","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1002\/hep.25776","article-title":"Oncogene-specific formation of chemoresistant murine hepatic cancer stem cells","volume":"56","author":"Chow","year":"2012","journal-title":"Hepatology"},{"key":"2022060815414206100_bib70","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.ajpath.2013.12.002","article-title":"Hydrodynamic transfection for generation of novel mouse models for liver cancer research","volume":"184","author":"Chen","year":"2014","journal-title":"Am J Pathol"}],"container-title":["Cancer Prevention Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerpreventionresearch\/article-pdf\/13\/11\/911\/1731307\/911.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerpreventionresearch\/article-pdf\/13\/11\/911\/1731307\/911.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T12:08:03Z","timestamp":1654690083000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerpreventionresearch\/article\/13\/11\/911\/47292\/Immune-Checkpoint-Inhibition-is-Safe-and-Effective"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,1]]},"references-count":70,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2020,11,3]]},"published-print":{"date-parts":[[2020,11,1]]}},"URL":"https:\/\/doi.org\/10.1158\/1940-6207.capr-20-0200","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/1940-6207.22534823","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1940-6207.22534835.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1940-6207.22534835","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1940-6207.22534826","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1940-6207.22534838","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1940-6207.22534832.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1940-6207.22534826.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1940-6207.22534820.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1940-6207.22534820","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1940-6207.22534832","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1940-6207.22534823.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1940-6207.22534838.v1","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/1940-6207.c.6547667.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1940-6207.c.6547667","asserted-by":"object"}]},"ISSN":["1940-6207","1940-6215"],"issn-type":[{"value":"1940-6207","type":"print"},{"value":"1940-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,1]]}}}